Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409125 | 0.99 | CCR5 (0.45) | CCR5KCNH2CCR2SMN1; SMN2LMNA | |
| SCHEMBL6415609 | 0.93 | CCR5 (0.44) | CCR5KCNH2CCR2 | |
| SCHEMBL6408703 | 0.93 | CCR5 (0.48) | CCR5KCNH2CCR2 | |
| Hydrochloric Acid SCHEMBL6415607 | 0.92 | CCR5 (0.43) | CCR5KCNH2CCR2 | |
| Hydrochloric Acid SCHEMBL6408699 | 0.92 | CCR5 (0.47) | CCR5KCNH2CCR2 | |
| SCHEMBL6413530 | 0.92 | CCR2 (0.45) | CCR5CCR2SMN1; SMN2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6413525 | 0.91 | CCR2 (0.44) | CCR5CCR2SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6409940 | 0.90 | CCR5 (0.42) | CCR5KCNH2CCR2 | |
| SCHEMBL6410286 | 0.90 | HDAC11 (0.38) | CCR5SMN1; SMN2LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL6411214 | 0.89 | CCR5 (0.47) | CCR5KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR5 4/4885KCNH2 3076/4885CCR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.